IGM Biosciences Inc.’s stock tumbled 14% Tuesday, as analysts weighed in with dismay on the company’s pivot away from ...

The following is a summary of “Altered B-cell, plasma cell and antibody immune profiles in blood of systemic mastocytosis,” ...

poorly defined disorder characterized by low serum levels of IgG and usually IgA or IgM. Common clinical picture may result from multiple mechanisms. A failure of T-cell and B-cell cooperation ...

IGM stock crashed Tuesday after the biotech company scrapped development of a cancer drug and announced three of its executives stepped down.

Imvotamab is a bispecific T cell engaging IgM antibody targeting both CD3 and CD20 proteins. Management believes Imvotamab could deliver significant advantages over existing B cell therapies as it ...

type I consists of a monoclonal immunoglobulin (IgM, IgG, or IgA), type II includes polyclonal IgG plus monoclonal IgM with rheumatoid-factor activity, and type III comprises polyclonal IgG ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Pronounced B-lymphocyte depletion and lower serum IgM, as reported in LON patients ... as seen in lymphoma patients after autologous stem cell transplant and in rheumatic patients under concurrent ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

IGM Biosciences, Inc. (IGMS) shares ended the last trading session 11.6% higher at $17.68. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...